Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

Tampa Bay Lightning forward Michael Eyssimont was diagnosed with Crohn's disease eight years ago at the age of 21. Since then ...

A new machine learning model predicts the need for temporary stoma formation after intestinal resection in Crohn’s disease, ...

A new study links mitochondrial dysfunction to Crohn’s disease, shifting how scientists approach treatment and opening doors ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Focus on Precision Medicine: Certification covers Biomerica's food intolerance products developed to support patients with Crohn's Disease and Ulcerative Colitis (UC), both of which are chronic and ...

Steven Frayne, aka Dynamo, has revealed he "couldn't even shuffle cards" as he opened up on a debilitating health condition.

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

A 10-year-old Indiana boy with Crohn's disease recently experienced a dream come true thanks to the Sunshine Foundation.

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...